×

Jaleko Acadêmicos's video: Atualiza es no Tratamento Farmacol gico da COVID-19

@Atualizações no Tratamento Farmacológico da COVID-19
ATENÇÃO À CORREÇÃO A gente ama o Dr. Felipe Magalhães, a aula é super legal! Mas, dessa vez, o querido professor acabou trocando duas palavras: Com 15 minutos e 35 segundos, quando ele falou que os anticorpos não conseguiram "mostrar mortalidade", na verdade, ele tava querendo dizer "mudar a mortalidade" Ah... E com 31 minutos e 15 segundos, é claro que ele estava falando que plasma convalescente é feito só para paciente hospitalar e não domiciliar. Essa aula foi gravada na manhã no dia 06/01/2021 e as coisas mudam e, às vezes, mudam rápido. Então, ontem à noite saiu um novo artigo sobre o uso de plasma convalescente em pacientes com sintomas muito recentes (menos de 72h) e, dessa vez, houve benefícios. Ainda não teve mudança na mortalidade, mas o estudo mostrou que diminui a insuficiência respiratória. Quando vocês assistirem a essa aula, vão ver que o professor Felipe fala que talvez pudesse funcionar nos pacientes com casos mais leves e que ainda estavam em casa, mas que isso era difícil de fazer. Pois é, o estudo mostrou que nos pacientes que acabaram de chegar no hospital, com menos de 3 dias de doença e que ainda não possuem insuficiência respiratória, essa é uma estratégia que pode trazer benefícios. https://www.nejm.org/doi/full/10.1056/NEJMoa2033700?query=featured_home "Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults" E Saiu um novo estudo no dia seguinte com o tocilizumab, uma droga anti-IL6 que não mudou a mortalidade, mas diminui insuficiência respiratória. O artigo está aqui: https://www.nejm.org/doi/full/10.1056/NEJMoa2030340 #:~:text=Tocilizumab%2C%20an%20anti%E2%80%93interleukin%2D,the%20United%20States%20and%20globally. e o prof. Felipe já gravou um vídeo comentando estes dois artigos lá na plataforma!! E abaixo segue alguns artigos selecionados pelo professor sobre o assunto: Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 June 18, 2020 N Engl J Med 2020; 382:2411-2418 DOI: 10.1056/NEJMoa2012410 Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 November 19, 2020. N Engl J Med 2020; 383:2030-2040 DOI: 10.1056/NEJMoa2022926 Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 November 19, 2020 N Engl J Med 2020; 383:2041-2052 DOI: 10.1056/NEJMoa2019014 A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 November 24, 2020 DOI: 10.1056/NEJMoa2021801 Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform the lancet rheumatology Published:November 05, 2020 DOI:https://doi.org/10.1016/S2665-9913(20)30378-7 Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data BMJ 2020; 369 doi: https://doi.org/10.1136/bmj.m1844 Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data BMJ 2020; 369 doi: https://doi.org/10.1136/bmj.m1844 Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 Nov 20, 2020DOI:https://doi.org/10.1016/j.eclinm.2020.100645 Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial Sept 4, 2020 https://doi.org/10.1016/ S0140-6736(20)31862-6 A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia Nejm Nov 24, 2020 DOI: 10.1056/NEJMoa2031304 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569. Epub 2020 Apr 29. Remdesivir for the Treatment of Covid-19 - Final Report. NEJM. 2020;383(19):1813. Epub 2020 Oct 8. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(11):1048. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371:m3939. Epub 2020 Oct 22. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. NEJM Nov 24, 2020 DOI: 10.1056/NEJMoa2031304 Inscreva-se aqui em nosso canal! Quer ter 48h de acesso ilimitado na plataforma? Então cadastre-se gratuitamente em nossa plataforma: https://bit.ly/315DiNN Instagram - https://bit.ly/2CENl31 Blog - https://bit.ly/2Q54yWh Twitter - https://bit.ly/3haFgCb LinkedIn - https://bit.ly/3aA39AB Telegram - https://bit.ly/3gh9KkN Newsletter - https://bit.ly/32eosnq Podcast - https://spoti.fi/2EkLdhv Saúde Inova - https://www.instagram.com/saudeinova/ vistaseu@jaleko.com.br

85

14
Jaleko Acadêmicos
Subscribers
66.7K
Total Post
748
Total Views
14.3K
Avg. Views
285.1
View Profile
This video was published on 2021-01-08 03:30:11 GMT by @Jaleko-Acad%c3%aamicos on Youtube. Jaleko Acadêmicos has total 66.7K subscribers on Youtube and has a total of 748 video.This video has received 85 Likes which are higher than the average likes that Jaleko Acadêmicos gets . @Jaleko-Acad%c3%aamicos receives an average views of 285.1 per video on Youtube.This video has received 14 comments which are higher than the average comments that Jaleko Acadêmicos gets . Overall the views for this video was lower than the average for the profile.Jaleko Acadêmicos #:~:text=Tocilizumab%2C%20an%20anti%E2%80%93interleukin%2D,the%20United%20States%20and%20globally. e has been used frequently in this Post.

Other post by @Jaleko Acad%c3%aamicos